DEF 14A

Company

Theravance Biopharma, Inc.

Filed

March 17, 2015

Period of Report

April 22, 2015

Accession Number

0001047469-15-002361

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →